Finanzwire
COMMUNIQUÉ DE PRESSE

par ABIONYX (EPA:ABNX)

Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract

image 

 

Press release

 

Half-yearly report on the liquidity contract  with TP ICAP (Europe) SA

Under the liquidity contract entered into by ABIONYX Pharma with TP ICAP (Europe) SA, the following assets were included in the liquidity account at June 30, 2025:

•         Number of shares: 162,298

•         Cash balance: 86,279.52 €

During the 1st half of 2025, a total of :

PURCHASE

223,631 shares

275,707.78 €

253 transactions

SALE

214,077 shares

272,643.70 €

226 transactions

As a reminder, at the half-yearly balance sheet date of December 31, 2024, the following assets were included in the liquidity account:

•         Number of shares: 152,744 shares

•         Cash balance: 90,498.64 €

When the liquidity contract was set up, the following resources were made available:

•         Number of shares: 131,000 shares

•         Cash balance: 40,801.20 €

ANNEX H1 2025

 

Purchases

Sales

ABNX FP

number of

transactions

Number of shares

Capital in EUR

number of

transactions

Number of shares

Capital in EUR

Total

253

223,631

275,707.78

226

214,077

272 ,643.696

20250101

0

0

0,00

0

0

0,00

20250102

1

1

1,20

1

1

1,20

20250103

4

4 731

5 598,24

1

1

1,20

20250106

2

2 151

2 555,39

1

1

1,19

20250107

2

2 091

2 475,76

2

2

2,41

20250108

1

1

1,21

6

16 781

20 838,45

20250109

1

1

1,28

3

4 091

5 261,22

20250110

5

6 674

8 375,50

1

1

1,30

20250113

2

2 321

2 915,20

1

1

1,28

20250114

2

2 251

2 827,26

1

1

1,26

20250115

3

2 283

2 834,77

2

1 364

1 732,25

20250116

2

2 181

2 708,83

2

54

68,58

20250117

1

1

1,27

5

12 861

16 681,79

20250120

2

2 411

3 134,32

3

4 051

5 396,12

20250121

4

5 141

6 583,61

1

1

1,29

20250122

2

2 391

3 003,11

1

1

1,27

20250123

2

2 321

2 910,53

2

98

125,61

20250124

2

2 251

2 827,28

2

3

3,85

20250127

3

3 001

3 731,25

1

1

1,25

20250128

1

1

1,24

1

1

1,24

20250129

4

3 726

4 523,13

1

1

1,24

20250130

2

300

362,40

1

1

1,21

20250131

2

16

19,30

4

8 891

11 103,15

20250203

3

3 141

3 830,03

2

72

90,00

20250204

2

2 251

2 710,21

1

1

1,21

20250205

1

1

1,22

2

2

2,44

20250206

2

2 181

2 630,31

1

1

1,23

20250207

2

2 131

2 544,42

1

1

1,20

20250210

1

1

1,22

2

2

2,44

20250211

1

1

1,20

1

1

1,20

20250212

1

1

1,20

4

6 289

7 736,41

20250213

3

3 011

3 659,43

2

2

2,49

20250214

1

1

1,23

2

2

2,46

20250217

2

250

300,50

3

4 441

5 480,40

20250218

1

1

1,24

4

4 329

5 463,59

20250219

3

3 201

3 941,54

2

392

494,68

20250220

1

1

1,33

6

15 961

21 228,13

20250221

1

1

1,31

2

738

972,68

20250224

3

3 621

4 697,72

1

1

1,32

20250225

1

1

1,33

5

11 351

15 354,69

20250226

3

3 811

5 134,77

3

3 591

4 962,95

20250227

3

3 821

5 140,51

1

1

1,35

20250228

4

5 691

7 466,21

1

1

1,35

20250303

1

1

1,30

6

12 891

17 168,66

20250304

4

6 181

8 071,89

2

2

2,69

20250305

2

2

2,54

2

1 559

2 023,55

20250306

2

2 921

3 727,21

1

1

1,29

20250307

3

3 871

4 913,61

1

1

1,27

20250310

3

3 721

4 715,77

1

1

1,27

20250311

4

5 571

6 855,74

1

1

1,26

20250312

1

1

1,24

1

1

1,24

20250313

2

424

517,30

3

4 051

5 072,04

20250314

3

3 571

4 439,97

1

1

1,25

20250317

2

2 561

3 129,56

1

1

1,24

20250318

1

1

1,24

1

1

1,24

20250319

2

2 481

3 031,78

1

1

1,22

20250320

2

2 411

2 941,43

3

4 231

5 297,39

20250321

1

1

1,26

7

19 891

25 919,78

20250324

3

3 627

4 672,00

2

972

1 281,10

20250325

2

2 901

3 690,09

1

1

1,29

20250326

1

1

1,29

1

1

1,29

20250327

1

1

1,28

1

1

1,28

20250328

1

1

1,28

1

1

1,28

20250331

2

1 862

2 346,13

1

1

1,27

20250401

5

9 031

11 067,11

1

1

1,27

20250402

4

5 341

6 540,66

1

1

1,24

20250403

3

3 301

4 051,43

1

1

1,23

20250404

5

7 581

9 022,58

1

1

1,24

20250407

7

10 871

12 406,55

1

1

1,19

20250408

2

1 338

1 493,23

5

9 741

11 244,94

20250409

4

4 202

4 770,74

1

1

1,14

20250410

1

1

1,18

5

13 821

16 335,50

20250411

2

2 451

2 857,87

1

1

1,17

20250414

2

911

1 060,43

2

2

2,38

20250415

2

2 351

2 741,29

1

1

1,19

20250416

2

640

744,96

1

1

1,16

20250417

1

1

1,19

2

2 231

2 659,35

20250418

0

0

0,00

0

0

0,00

20250421

0

0

0,00

0

0

0,00

20250422

1

1

1,20

3

4 481

5 386,40

20250423

1

1

1,19

3

4 321

5 280,47

20250424

1

1

1,23

2

413

508,82

20250425

1

1

1,21

1

1

1,21

20250428

1

1

1,23

2

249

306,27

20250429

2

2

2,44

1

1

1,23

20250430

2

1 865

2 256,68

1

1

1,24

20250501

0

0

0,00

0

0

0,00

20250502

1

1

1,22

2

2 071

2 551,46

20250505

6

10 811

12 763,44

1

1

1,24

20250506

3

3 021

3 629,31

2

2

2,46

20250507

1

1

1,23

1

1

1,23

20250508

1

1

1,21

1

1

1,21

20250509

1

1

1,23

1

1

1,23

20250512

3

2 191

2 629,20

1

1

1,20

20250513

1

1

1,23

2

4

4,93

20250514

1

1

1,23

1

1

1,23

20250515

1

1

1,23

1

1

1,23

20250516

2

2 061

2 493,83

1

1

1,23

20250519

1

1

1,23

1

1

1,23

20250520

1

1

1,21

4

9 071

11 364,29

20250521

1

1

1,24

2

2

2,49

20250522

1

1

1,24

3

4 371

5 455,20

20250523

1

1

1,26

4

8 381

10 768,00

20250526

1

1

1,30

2

2 001

2 601,30

20250527

1

1

1,31

4

7 871

10 396,13

20250528

1

1

1,33

3

3 579

4 767,23

20250529

4

6 071

7 774,61

1

1

1,29

20250530

1

1

1,29

1

1

1,29

20250602

1

1

1,30

2

474

619,98

20250603

1

1

1,31

1

1

1,31

20250604

3

3 771

4 839,51

1

1

1,29

20250605

1

1

1,26

1

1

1,26

20250606

1

1

1,28

1

1

1,28

20250609

1

1

1,28

1

1

1,28

20250610

1

1

1,29

2

1 951

2 520,69

20250611

3

3 002

3 833,87

1

1

1,30

20250612

3

3 621

4 589,10

1

1

1,30

20250613

3

3 511

4 400,52

1

1

1,26

20250616

2

300

372,00

1

1

1,24

20250617

1

1

1,25

1

1

1,25

20250618

2

961

1 180,13

1

1

1,25

20250619

1

1

1,25

1

1

1,25

20250620

2

2 491

3 058,95

1

1

1,23

20250623

3

3 301

4 031,62

1

1

1,22

20250624

1

1

1,23

1

1

1,23

20250625

2

2 361

2 852,09

1

1

1,21

20250626

1

1

1,23

1

1

1,23

20250627

1

1

1,23

1

1

1,23

20250630

4

4 761

5 678,38

1

1

1,20

About ABIONYX Pharma  

ABIONYX Pharma is a new-generation biotechnology company whose aim is to contribute to healthcare through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to offer drugs for the treatment of kidney and ophthalmological diseases, or new apoA-1 vectors used for targeted drug delivery.


 

 

Contacts 

NewCap 

Investor Relations Louis-Victor Delouvrier  abionyx@newcap.eu  +33 (0)1 44 71 98 53 NewCap          

Media Relations  Arthur Rouillé abionyx@newcap.eu 

+33 (0)1 44 71 00 15

Liquidity Contract Half-yearly Report Assets ABIONYX Pharma TP ICAP SA
Voir toutes les actualités de ABIONYX